RESEARCH ARTICLE
SA JOURNAL OF DIABETES & VASCULAR DISEASE
34. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G,
et al
. Flow-mediated vasodilation
and the risk of developing hypertension in healthy postmenopausal women.
J Am
Coll Cardiol
2004;
44
: 1636−640.
35. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ,
et al
. Non-invasive
assessment of endothelial function: which technique?
J Am Coll Cardiol
2006;
48
: 1846−1850.
36. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S,
et al
. Close relation of
endothelial function in the human coronary and peripheral circulations.
J Am Coll
Cardiol
1995;
26
: 1235−1241.
37. Reaven GM. Insulin resistance and human disease: a short history.
J Basic Clin
Physiol Pharmacol
1998;
9
: 387−406.
38. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G,
et al
. Obesity/
insulin resistance is associated with endothelial dysfunction. Implications for the
syndrome of insulin resistance.
J Clin Invest
1996;
97
: 2601−2610.
39. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide
production and insulin sensitivity. A physiological link with implications for
pathogenesis of cardiovascular disease.
Circulation
1996;
93
: 1331−1333.
40. Smits P1, Williams SB, Lipson DE, Banitt P, Rongen GA,
et al
. Endothelial
release of nitric oxide contributes to the vasodilator effect of adenosine in
humans.
Circulation
1995;
92
: 2135−2141.
41. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S,
et al
. Obesity and
body fat distribution induce endothelial dysfunction by oxidative stress: protective
effect of vitamin C.
Diabetes
2001;
50
: 159−165.
42. Vigili de Kreutzenberg S, Kiwanuka E, Tiengo A, Avogaro A. Visceral obesity
is characterized by impaired nitric oxide-independent vasodilation.
Eur Heart J
2003;
24
: 1210−1215.
43. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin
contributes to basal vascular tone and endothelial dysfunction in human obesity
and type 2 diabetes.
Diabetes
2002;
51
: 3517−3523.
44. Cardillo C, Campia U, Bryant MB, Panza JA . Increased activity of endogenous
endothelin in patients with type II diabetes mellitus.
Circulation
2002;
106
:
1783−1787.
45. Woo KS, Chook P, Yu CW, Sung RY, Qiao M,
et al
. Effects of diet and exercise
on obesity-related vascular dysfunction in children.
Circulation
2004;
109
:
1981−1986.
46. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S,
et al
. Lifestyle modification
improves endothelial function in obese subjects with the insulin resistance
syndrome.
Diabetes Care
2003;
26
: 2119−2125.
47. Raitakari M, Ilvonen T, Ahotupa M, Lehtimäki T, Harmoinen A,
et al
.
Weight reduction with very-low-caloric diet and endothelial function in
overweight adults: role of plasma glucose.
Arterioscler Thromb Vasc Biol
2004;
24
:124−128.
48. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between
insulin resistance and endothelial dysfunction: molecular and pathophysiological
mechanisms.
Circulation
2006;
113
: 1888−1904.
49. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease.
N
Engl J Med
2005;
352
: 1685−1695.
50. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G,
et al
. C-reactive
protein and other circulating markers of inflammation in the prediction of
coronary heart disease.
N Engl J Med
2004;
350
: 1387−1397.
51. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active”
coronary artery disease.
Am J Cardiol
1990;
65
: 168−172.
52. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S,
et al
. Elevated
C-reactive protein levels and impaired endothelial vasoreactivity in patients with
coronary artery disease.
Circulation
2000;
102
: 1000−1006.
53. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM,
et al.
Brachial artery
vasodilator function and systemic inflammation in the Framingham Offspring
Study.
Circulation
2004;
110
: 3604−3609.
54. Williams IL, Chowienczyk PJ, Wheatcroft SB, Patel A, Sherwood R,
et al
. Effect
of fat distribution on endothelial-dependent and endothelial-independent
vasodilatation in healthy humans.
Diabetes Obes Metab
2006;
8
: 296−301.
55. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A,
et al.
Effect of potentially
modifiable risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study.
Lancet
2004;
364
: 937−952.
Lipanthyl + Statin Better Outcome
S3 LIPANTHYL
®
PJ (DFK FDSVXOH FRQWDLQV PJ IHQR¿EUDWH PLFURQLVHG 5HJ 1R
)RU IXOO SUHVFULELQJ LQIRUPDWLRQ UHIHU WR WKH SDFNDJH
LQVHUW DSSURYHG E\ WKH 0HGLFLQHV 5HJXODWRU\ $XWKRULW\ 'DWH RI 3XEOLFDWLRQ RI WKLV 3URPRWLRQDO 0DWHULDO -DQXDU\
$EERWW /DERUDWRULHV 6 $ 3W\ /LPLWHG
$EERWW 3ODFH *ROI &OXE 7HUUDFH &RQVWDQWLD .ORRI
7HO 1R
3URPR 1R =$(/,/
References: 1.
)DUQLHU 0 8SGDWH RQ WKH FOLQLFDO XWLOLW\ RI IHQR¿EUDWH LQ PL[HG GLVOLSLGHPLDV PHFKDQLVPV RI DFWLRQ DQG UDWLRQDO SUHVFULELQJ
Vasc Health Risk
Management
4
Scripting a
Statin
alone may have some
limitations - there could be something missing in
the management of mixed dyslipidaemia to reach
non-HDL-C goals.
Lipanthyl and Statins
work
better together as an ideal treatment that can
effectively reduce cardiovascular risk associated
with elevated triglyceride and low HDL-C levels.
1
Imagine if Jimi Hendrix had never
picked up a guitar. How would this
missing piece have affected our
history, our culture, our musical
heritage? Would rock have
disappeared in a purple haze?
Don’t leave out the piece that several guidelines
are recommending for correction of mixed
dyslipidaemia. Consider scripting Lipanthyl together
with a Statin for broader lipid management.
1
HDL-C = High density lipoprotein cholesterol
THE MISSING
PIECE IN LIPID
MANAGEMENT
